Castle Biosciences, Inc. (CSTL) Stock
CSTL Key Statistics
About Castle Biosciences, Inc.
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.
CEO: Derek J. Maetzold. Company website
CSTL — Frequently Asked Questions
What is the CSTL stock price today?
Castle Biosciences, Inc. (CSTL) trades at $35.34, down 3.92% on the day, as of Sep 20, 2026 14:59 UTC.
What is Castle Biosciences, Inc.'s market cap?
Castle Biosciences, Inc. has a market capitalisation of $1.08B, calculated from the live CSTL share price and shares outstanding.
What is the P/E ratio of CSTL?
CSTL has no meaningful price-to-earnings ratio: Castle Biosciences, Inc. lost $0.66 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Castle Biosciences, Inc. make?
Castle Biosciences, Inc. generated revenue of $357.28M over the trailing twelve months, which puts the stock at 3.02 times sales.
What is the 52-week range for CSTL?
CSTL has traded between $17.72 and $44.13 over the past 52 weeks, and the last price is 19.9% below that high.
Is Castle Biosciences, Inc. profitable?
No. Castle Biosciences, Inc. is loss-making, with a net margin of -5.43% over the trailing twelve months.
What is the analyst price target for CSTL?
Wall Street analysts rate CSTL Buy, with an average price target of $39.00, 10.4% above the current price.
What sector is Castle Biosciences, Inc. in?
Castle Biosciences, Inc. is classified under the Healthcare sector and the Medical - Diagnostics & Research industry, and is domiciled in US.
Who is the CEO of Castle Biosciences, Inc.?
Derek J. Maetzold is the chief executive of Castle Biosciences, Inc., which employs 1,002 people.
Where can I track CSTL in real time?
QFI Terminal shows CSTL with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See CSTL live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open CSTL in Terminal See plans